Ensuring value, access & uptake of innovative medicines & vaccines, now & in the future
Transforming lives, raising productivity
A new report from PwC for the ABPI shows that, while the NHS has made progress in recent years, access to medicines in the UK remains poor especially in comparison to other developed countries.
UK medicine pricing
Medicines bring huge value to NHS patients. The development of new medicines is uncertain, costly, and involves significant rates of failure. The pharmaceutical industry spends $160 billion per year on research and development.
NICE methods and process evolution
NICE continues to evolve its methods and processes for evaluating new medicines. Making changes that support patient access remains a priority for the ABPI.
Advanced Therapy Medicinal Products (ATMPs)
Advanced Therapy Medicinal Products (ATMPs) are recognised for their potential to revolutionise the way diseases are treated and to transform patient outcomes.
Patient access to combination therapies
A combination therapy combines two or more individual medicines (components) into a single treatment regimen.
Appropriate prescribing
Prescription medicines are important therapeutic options which can be prescribed in order to prevent, treat or cure diseases and symptoms.
Vaccines
Every year, 2 – 3 million lives are saved across the world because of immunisation and only clean water rivals vaccines at reducing infectious diseases and deaths.
Medicine supply
Every day millions of patients rely on medicines supplied by the pharmaceutical industry.
The manufacture and selling of counterfeit medicines is an issue of increasing concern throughout the world. There are potentially fatal consequences for those who inadvertently take such products.
The Falsified Medicines Directive is legislation passed by the European Union Parliament, which aims to increase the security of the manufacturing and delivery of medicines across Europe and protect patients and prevent falsified medicines from entering the supply chain.